Aligos Therapeutics, Inc, a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 (NCT05090111). The clinical trial is evaluating Aligos
